Persistent Luminescence Nanoparticles Excitable in situ for in vivo Optical Imaging, in vivo Multimodal Optical-MRI Imaging, and Theranostics
AssigneeCentre National de la Recherche Scientifique (CNRS)
InventorsThomas Maldiney, Cyrille Richard, Daniel Scherman, Didier Gourier, Bruno Viana, Aurelie Bessiere
Life of this patent
Estimating the term…
Abstract
Multimodal optical and magnetic resonance imaging methods based on the use of persistent luminescence nanoparticles. Use of mesoporous persistent luminescence <<core-shell>> complexes for theranostic applications.
Claims19
An in vivo optical imaging method of a human or animal body, comprising the following steps:
- a) exciting the persistent luminescence of nanoparticles by in vivo irradiation of all or part of the human or animal body at a wavelength between 550 and 1000 nm, said nanoparticles being previously administered to the human or animal body, and said nanoparticles emitting photons at wavelengths between 550 and 1000 nm for at least 0.01 second, after light excitation at wavelengths between 550 and 1000 nm, and said nanoparticles comprising a nanomaterial formed of a matrix selected from among gallates, aluminates, indates, and their mixed compounds gallo-germanates, gallo-aluminates, gallo-indates, gallium oxides, indium oxides, magnesium oxides, zinc and gallium oxysulfides, zinc and gallium oxyselenides, zinc and gallium oxytellurides, said matrix being doped with a transition metal or lanthanide selected from among chromium, europium, cerium, nickel, iron, copper and cobalt;
- and
- b) detecting the nanoparticles in vivo in all or part of the human or animal body by measuring the persistent luminescence of the nanoparticles via optical imaging.
A bimodal in vivo imaging method of a human or animal body comprising the following steps:
- a) exciting the persistent luminescence of the nanoparticles by in vivo irradiation of all or part of the human or animal body at a wavelength between 550 and 1000 nm, said nanoparticles being previously administered to the human or animal body, and said nanoparticles emitting photons at wavelengths between 550-1000 nm for at least 0.01 second under excitation light at wavelengths between 550 and 1000 nm, said nanoparticles having paramagnetic properties and said nanoparticles comprising a nanomaterial formed of a matrix from among gallates, aluminates, indates, gallium oxides, indium oxides, magnesium oxides, gallo-germanates, alumina-gallates, zinc and gallium oxysulfides, zinc an gallium oxyselenides, zinc and gallium oxytellurides, said matrix being doped with a transition metal or lanthanide selected from among chromium, europium, cerium, nickel, iron, copper and cobalt and with at least one paramagnetic element selected from among Cr3+;
- Mn2+;
- Gd3+;
- Fe+ and Ni3+;
- b) detecting the nanoparticles in vivo in all or part of the human or animal body by measuring the persistent luminescence of the nanoparticles using optical imaging;
- and
- c) detecting the nanoparticles in vivo in all or part of the animal body by magnetic resonance imaging.
A nanoparticle comprising the nanomaterial ZnGa2(1-x-y)Cr2xGd2yO4 with x between 0.001 and 0.0075 and y between 0.01 and 0.08.
Dependencies are inferred from the claim text.